Tenderwize
Retour à la recherche

Open-House non-exclusive rebate agreement for Sultamicillin

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Feb 29, 2028 · 550 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Sultamicillin (ATC-Code nach WHO: J01CR04)

52/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

52 / 100

Complexité

58 / 100

Facteurs de risque

The participation documents are not fully available in the extracted text; key instructions are said to be in 'Anschrei...

Demand and purchase volume are explicitly unknown, and minimum quantities are not guaranteed.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2028
  • Non-exclusive rebate agreement for pharmaceutical products containing Sultamicillin (ATC J01CR04).
  • Open-House participation model with contract conclusion available to all interested pharmaceutical companies meeting the conditions.
Afficher le résumé complet

This is an Open-House framework-style pharmaceutical supply arrangement for Sultamicillin (CPV 33600000) led by AOK PLUS. It is non-exclusive, open to all interested pharmaceutical companies that meet the stated participation conditions, with no individual negotiations and no guaranteed minimum purchase volume. Participation documents are available via DTVP, but the extracted procurement documents themselves were not provided for analysis beyond the XML notice text. Submission is electronic via the portal communication function, not via the bidder tool, and the first participation deadline is 2026-02-03; the arrangement ends no later than 2028-02-29.

Risques

The participation documents are not fully available in the extracted text; key instructions are said to be in 'Anschrei...

Demand and purchase volume are explicitly unknown, and minimum quantities are not guaranteed.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal product.

Administrative

  • Participation documents must be submitted as specified in the documents 'Anschreiben' and 'Erläuterungen der Vertragsbedingungen'.
  • An 'Eigenerklärung zum Nichtvorliegen von Ausschlussgründen' must be completed and submitted.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Open-House non-exclusive rebate agreement for Sultamicillin

Supply arrangement for non-exclusive pharmaceutical rebate agreements under Section 130a(8) SGB V for the active ingredient Sultamicillin (ATC J01CR04). The lot is an Open-House model: any interested pharmaceutical company may participate if it meets and accepts the stated conditions. No exclusivity, no individual negotiations, and no guaranteed minimum purchase volume are stated. Place of performance is Dresden, Germany, with performance covering Saxony and Thuringia as stated in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Feb 2026 - Feb 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 29, 2028

Détails de la procédure

Date de publication
18 Dec 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
845306-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30